TCH-1030 targeting on topoisomerase i induces S-phase arrest, DNA fragmentation, and cell death of breast cancer cells

Yu Peng Liu, Hui Ling Chen, Cherng Chyi Tzeng, Pei-Jung Lu, Cheng Wei Lo, Yu Cheng Lee, Chih Hua Tseng, Yeh Long Chen, Chia Ning Yang

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Camptothecin (CPT) and its derivatives are powerful anticancer agents, but these compounds are chemically unstable due to their α-hydroxy lactone six-membered E-ring structure, which is essential for trapping topoisomerase I (topo I)-DNA cleavage complexes. Moreover, the reversibility of trapping the topo I-DNA cleavage complex and the tight binding of CPTs to human serum albumin limit the levels of available active drug. CPT analogs are the only clinically available drugs that target topo I. Owing to the clinical importance of CPT analogs, the development of new anticancer agents which inhibit topo I is urgently needed. In the present study, we report the synthesis, biologic evaluation, and molecular mechanism of a series of substituted indeno[1,2-c]quinoline derivatives against the growth of several human cancer cell lines. We found that 9-methoxy-6-(piperazin-1-yl)-11H-indeno[1,2-c] quinoline-11-one O-3-(dimethylamino)propyl oxime (TCH-1030) intercalated into DNA and preferentially inhibited DNA topo I relaxation. Flow cytometric analysis and BrdU incorporation assays indicate that TCH-1030 alters cell cycle progression, induces S-phase arrest, and causes DNA polyploidy (>4 N) that is distinct from the typical G2-M arrest reported with known topoisomerase toxins. Our data indicate that TCH-1030 induces caspase 3 activation, PARP cleavage, γ-H2AX phosphorylation, and, consequently, DNA fragmentation and apoptosis. We also demonstrated that treatment with TCH-1030 significantly inhibits tumor growth in a BT483-xenograft nude mouse model. Taken together, we conclude that the primary mechanism of action of TCH-1030-induced cell cycle retardation and apoptosis-mediated DNA damage involves DNA binding and intercalation as well as topo I inhibition.

Original languageEnglish
Pages (from-to)383-393
Number of pages11
JournalBreast Cancer Research and Treatment
Volume138
Issue number2
DOIs
Publication statusPublished - 2013 Apr 1

Fingerprint

DNA Fragmentation
Type I DNA Topoisomerase
S Phase
Cell Death
Breast Neoplasms
Camptothecin
DNA Cleavage
Antineoplastic Agents
DNA
Cell Cycle
Apoptosis
Polyploidy
Lactones
Bromodeoxyuridine
Growth
Heterografts
Nude Mice
Serum Albumin
Caspase 3
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Liu, Yu Peng ; Chen, Hui Ling ; Tzeng, Cherng Chyi ; Lu, Pei-Jung ; Lo, Cheng Wei ; Lee, Yu Cheng ; Tseng, Chih Hua ; Chen, Yeh Long ; Yang, Chia Ning. / TCH-1030 targeting on topoisomerase i induces S-phase arrest, DNA fragmentation, and cell death of breast cancer cells. In: Breast Cancer Research and Treatment. 2013 ; Vol. 138, No. 2. pp. 383-393.
@article{ca89694710ae4d9e9de645b34a94d77d,
title = "TCH-1030 targeting on topoisomerase i induces S-phase arrest, DNA fragmentation, and cell death of breast cancer cells",
abstract = "Camptothecin (CPT) and its derivatives are powerful anticancer agents, but these compounds are chemically unstable due to their α-hydroxy lactone six-membered E-ring structure, which is essential for trapping topoisomerase I (topo I)-DNA cleavage complexes. Moreover, the reversibility of trapping the topo I-DNA cleavage complex and the tight binding of CPTs to human serum albumin limit the levels of available active drug. CPT analogs are the only clinically available drugs that target topo I. Owing to the clinical importance of CPT analogs, the development of new anticancer agents which inhibit topo I is urgently needed. In the present study, we report the synthesis, biologic evaluation, and molecular mechanism of a series of substituted indeno[1,2-c]quinoline derivatives against the growth of several human cancer cell lines. We found that 9-methoxy-6-(piperazin-1-yl)-11H-indeno[1,2-c] quinoline-11-one O-3-(dimethylamino)propyl oxime (TCH-1030) intercalated into DNA and preferentially inhibited DNA topo I relaxation. Flow cytometric analysis and BrdU incorporation assays indicate that TCH-1030 alters cell cycle progression, induces S-phase arrest, and causes DNA polyploidy (>4 N) that is distinct from the typical G2-M arrest reported with known topoisomerase toxins. Our data indicate that TCH-1030 induces caspase 3 activation, PARP cleavage, γ-H2AX phosphorylation, and, consequently, DNA fragmentation and apoptosis. We also demonstrated that treatment with TCH-1030 significantly inhibits tumor growth in a BT483-xenograft nude mouse model. Taken together, we conclude that the primary mechanism of action of TCH-1030-induced cell cycle retardation and apoptosis-mediated DNA damage involves DNA binding and intercalation as well as topo I inhibition.",
author = "Liu, {Yu Peng} and Chen, {Hui Ling} and Tzeng, {Cherng Chyi} and Pei-Jung Lu and Lo, {Cheng Wei} and Lee, {Yu Cheng} and Tseng, {Chih Hua} and Chen, {Yeh Long} and Yang, {Chia Ning}",
year = "2013",
month = "4",
day = "1",
doi = "10.1007/s10549-013-2441-1",
language = "English",
volume = "138",
pages = "383--393",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

TCH-1030 targeting on topoisomerase i induces S-phase arrest, DNA fragmentation, and cell death of breast cancer cells. / Liu, Yu Peng; Chen, Hui Ling; Tzeng, Cherng Chyi; Lu, Pei-Jung; Lo, Cheng Wei; Lee, Yu Cheng; Tseng, Chih Hua; Chen, Yeh Long; Yang, Chia Ning.

In: Breast Cancer Research and Treatment, Vol. 138, No. 2, 01.04.2013, p. 383-393.

Research output: Contribution to journalArticle

TY - JOUR

T1 - TCH-1030 targeting on topoisomerase i induces S-phase arrest, DNA fragmentation, and cell death of breast cancer cells

AU - Liu, Yu Peng

AU - Chen, Hui Ling

AU - Tzeng, Cherng Chyi

AU - Lu, Pei-Jung

AU - Lo, Cheng Wei

AU - Lee, Yu Cheng

AU - Tseng, Chih Hua

AU - Chen, Yeh Long

AU - Yang, Chia Ning

PY - 2013/4/1

Y1 - 2013/4/1

N2 - Camptothecin (CPT) and its derivatives are powerful anticancer agents, but these compounds are chemically unstable due to their α-hydroxy lactone six-membered E-ring structure, which is essential for trapping topoisomerase I (topo I)-DNA cleavage complexes. Moreover, the reversibility of trapping the topo I-DNA cleavage complex and the tight binding of CPTs to human serum albumin limit the levels of available active drug. CPT analogs are the only clinically available drugs that target topo I. Owing to the clinical importance of CPT analogs, the development of new anticancer agents which inhibit topo I is urgently needed. In the present study, we report the synthesis, biologic evaluation, and molecular mechanism of a series of substituted indeno[1,2-c]quinoline derivatives against the growth of several human cancer cell lines. We found that 9-methoxy-6-(piperazin-1-yl)-11H-indeno[1,2-c] quinoline-11-one O-3-(dimethylamino)propyl oxime (TCH-1030) intercalated into DNA and preferentially inhibited DNA topo I relaxation. Flow cytometric analysis and BrdU incorporation assays indicate that TCH-1030 alters cell cycle progression, induces S-phase arrest, and causes DNA polyploidy (>4 N) that is distinct from the typical G2-M arrest reported with known topoisomerase toxins. Our data indicate that TCH-1030 induces caspase 3 activation, PARP cleavage, γ-H2AX phosphorylation, and, consequently, DNA fragmentation and apoptosis. We also demonstrated that treatment with TCH-1030 significantly inhibits tumor growth in a BT483-xenograft nude mouse model. Taken together, we conclude that the primary mechanism of action of TCH-1030-induced cell cycle retardation and apoptosis-mediated DNA damage involves DNA binding and intercalation as well as topo I inhibition.

AB - Camptothecin (CPT) and its derivatives are powerful anticancer agents, but these compounds are chemically unstable due to their α-hydroxy lactone six-membered E-ring structure, which is essential for trapping topoisomerase I (topo I)-DNA cleavage complexes. Moreover, the reversibility of trapping the topo I-DNA cleavage complex and the tight binding of CPTs to human serum albumin limit the levels of available active drug. CPT analogs are the only clinically available drugs that target topo I. Owing to the clinical importance of CPT analogs, the development of new anticancer agents which inhibit topo I is urgently needed. In the present study, we report the synthesis, biologic evaluation, and molecular mechanism of a series of substituted indeno[1,2-c]quinoline derivatives against the growth of several human cancer cell lines. We found that 9-methoxy-6-(piperazin-1-yl)-11H-indeno[1,2-c] quinoline-11-one O-3-(dimethylamino)propyl oxime (TCH-1030) intercalated into DNA and preferentially inhibited DNA topo I relaxation. Flow cytometric analysis and BrdU incorporation assays indicate that TCH-1030 alters cell cycle progression, induces S-phase arrest, and causes DNA polyploidy (>4 N) that is distinct from the typical G2-M arrest reported with known topoisomerase toxins. Our data indicate that TCH-1030 induces caspase 3 activation, PARP cleavage, γ-H2AX phosphorylation, and, consequently, DNA fragmentation and apoptosis. We also demonstrated that treatment with TCH-1030 significantly inhibits tumor growth in a BT483-xenograft nude mouse model. Taken together, we conclude that the primary mechanism of action of TCH-1030-induced cell cycle retardation and apoptosis-mediated DNA damage involves DNA binding and intercalation as well as topo I inhibition.

UR - http://www.scopus.com/inward/record.url?scp=84879413417&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879413417&partnerID=8YFLogxK

U2 - 10.1007/s10549-013-2441-1

DO - 10.1007/s10549-013-2441-1

M3 - Article

VL - 138

SP - 383

EP - 393

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -